Tianyanxin Sun1, Bora Lee1, Jason Kinchen2, Erica T Wang1,3, Tania L Gonzalez1, Jessica L Chan1, Jerome I Rotter4, Yii-Der Ida Chen4, Kent Taylor4, Mark O Goodarzi3,5, Stephen S Rich6, Charles R Farber6, John Williams1,3, Margareta D Pisarska1,3. 1. Division of Reproductive Endocrinology and Infertility, Center for Reproductive Medicine, Cedars-Sinai Medical Center, Los Angeles, California. 2. Metabolon, Inc., Durham, North Carolina. 3. David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. 4. LA Biomed/Harbor-University of California, Los Angeles Medical Center, Torrance, California. 5. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. 6. Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia.
Abstract
Context: Maternal metabolic status reflects underlying physiological changes in the maternal-placental-fetal unit that may help identify contributors to adverse pregnancy outcomes associated with infertility and treatments used. Objective: To determine if maternal metabolomic profiles differ between spontaneous pregnancies and pregnancies conceived with fertility treatments that may explain the differences in pregnancy outcomes. Design: Metabolon metabolomic analysis and ELISAs for 17-β-estradiol and progesterone were performed during the late first trimester of pregnancy. Setting: Academic institution. Subjects: Women in the Spontaneous/Medically Assisted/Assisted Reproductive Technology cohort (N = 409), 208 of whom conceived spontaneously and 201 with infertility [non in vitro fertilization treatments (NIFT), n=90; in vitro fertilization (IVF), n=111]. Intervention: Mode of conception. Main Outcome Measures: Levels of of 806 metabolites within eight superpathways, 17-β-estradiol, and progesterone in maternal plasma in the late first trimester. Results: Metabolomic differences in the lipid superpathway (i.e., steroid metabolites, lipids with docosahexaenoyl acyl chains, acyl cholines), and xanthine and benzoate metabolites (P < 0.05) were significant among the spontaneous and two infertility groups, with greatest differences between the spontaneous and IVF groups. 17-β-estradiol and progesterone levels were significantly elevated in the infertility groups, with greatest differences between the spontaneous and IVF groups. Conclusion: Metabolomic profiles differ between spontaneous and infertility pregnancies, likely driven by IVF. Higher levels of steroids and their metabolites are likely due to increased hormone production from placenta reprogrammed from fertility treatments, which may contribute to adverse outcomes associated with infertility and the treatments used.
Context: Maternal metabolic status reflects underlying physiological changes in the maternal-placental-fetal unit that may help identify contributors to adverse pregnancy outcomes associated with infertility and treatments used. Objective: To determine if maternal metabolomic profiles differ between spontaneous pregnancies and pregnancies conceived with fertility treatments that may explain the differences in pregnancy outcomes. Design: Metabolon metabolomic analysis and ELISAs for 17-β-estradiol and progesterone were performed during the late first trimester of pregnancy. Setting: Academic institution. Subjects: Women in the Spontaneous/Medically Assisted/Assisted Reproductive Technology cohort (N = 409), 208 of whom conceived spontaneously and 201 with infertility [non in vitro fertilization treatments (NIFT), n=90; in vitro fertilization (IVF), n=111]. Intervention: Mode of conception. Main Outcome Measures: Levels of of 806 metabolites within eight superpathways, 17-β-estradiol, and progesterone in maternal plasma in the late first trimester. Results: Metabolomic differences in the lipid superpathway (i.e., steroid metabolites, lipids with docosahexaenoyl acyl chains, acyl cholines), and xanthine and benzoate metabolites (P < 0.05) were significant among the spontaneous and two infertility groups, with greatest differences between the spontaneous and IVF groups. 17-β-estradiol and progesterone levels were significantly elevated in the infertility groups, with greatest differences between the spontaneous and IVF groups. Conclusion: Metabolomic profiles differ between spontaneous and infertility pregnancies, likely driven by IVF. Higher levels of steroids and their metabolites are likely due to increased hormone production from placenta reprogrammed from fertility treatments, which may contribute to adverse outcomes associated with infertility and the treatments used.
Authors: Tanja G M Vrijkotte; Náthalie Krukziener; Barbara A Hutten; Karlijn C Vollebregt; Manon van Eijsden; Marcel B Twickler Journal: J Clin Endocrinol Metab Date: 2012-08-29 Impact factor: 5.958
Authors: Michael J Davies; Vivienne M Moore; Kristyn J Willson; Phillipa Van Essen; Kevin Priest; Heather Scott; Eric A Haan; Annabelle Chan Journal: N Engl J Med Date: 2012-05-05 Impact factor: 91.245
Authors: Sheree L Boulet; Russell S Kirby; Jennita Reefhuis; Yujia Zhang; Saswati Sunderam; Bruce Cohen; Dana Bernson; Glenn Copeland; Marie A Bailey; Denise J Jamieson; Dmitry M Kissin Journal: JAMA Pediatr Date: 2016-06-06 Impact factor: 16.193
Authors: Bora Lee; Lindsay L Kroener; Ning Xu; Erica T Wang; Alexandra Banks; John Williams; Mark O Goodarzi; Yii-der I Chen; Jie Tang; Yizhou Wang; Vineela Gangalapudi; Margareta D Pisarska Journal: Biol Reprod Date: 2016-10-12 Impact factor: 4.285
Authors: Margareta D Pisarska; Jessica L Chan; Kate Lawrenson; Tania L Gonzalez; Erica T Wang Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958
Authors: Frauke von Versen-Höynck; Sebastian Häckl; Elif Seda Selamet Tierney; Kirk P Conrad; Valerie L Baker; Virginia D Winn Journal: Hypertension Date: 2019-12-16 Impact factor: 10.190